Development of MEPS-UHPLC-MS/MS multistatin methods for clinical analysis

Bioanalysis. 2016 Feb;8(4):333-49. doi: 10.4155/bio.15.245. Epub 2016 Feb 9.

Abstract

Background: Statins are the microsomal 3-hydroxy-3methylglutaryl-coenzyme A reductase inhibitors used for the treatment of hypercholesterolemia. Some recent studies revealed also the extra-lipid effects and anticancer activities. Due to the wide incidence of cancer diseases, the number of studies dealing with anticancer statin activities has grown in recent years. Development of one universal multistatin method will be a very convenient way of providing practical and economical multiple statin analysis. Results/methodology: Fast and sensitive methods for determination of seven clinically relevant statins, their interconversion products and metabolites (17 analytes in total) in biological samples using microextraction by packed sorbent for sample preparation and UHPLC-MS/MS for subsequent analysis were developed and validated. Three MS platforms with different ion sources, transfer optics, collision cell technologies and scan speed parameters were compared.

Conclusion: Significant differences among the methods were observed in terms of selectivity and sensitivity. Microextraction by packed sorbent was successful in the extraction of all 17 analytes from biological matrix.

Keywords: MEPS; SPE; UHPLC–MS/MS; bioanalysis; dwell time; interconversion; multianalyte; protein precipitation; statins; triple quadrupole systems.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Blood Chemical Analysis / methods*
  • Chemical Precipitation
  • Chromatography, High Pressure Liquid / methods*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / blood*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / chemistry
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / isolation & purification*
  • Limit of Detection
  • Reproducibility of Results
  • Solid Phase Microextraction / methods*
  • Tandem Mass Spectrometry / methods*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors